ARCHIVES

Legacy CEO Cheryl Healton says foundation could serve as funder for research on “potentially reduced-exposure products.”

This article is from The Cancer Letter archive.

Vol. 30 No. 41 | October 29, 2004

Download PDF Visit The Full Archive

Related Articles

Phase III Trial Would Give Clearer Picture of C225 Role

March 8, 2002

IOM Omics Committee Offers Blueprint to Prevent Other Duke-Style Disasters

March 23, 2012

Greenwald Says NCI Still Committed To Year 2000 Goals

January 11, 1991

Taxol Approved By FDA For Ovarian Cancer; Bristol Sets Price Tier In Line With Platinum

January 8, 1993

Cancer Groups Support Senate FDA Bill; Reform Measure Face Uncertain future

March 1, 1996

Program Announcement Completes NCI switch To Control Research

April 16, 1982